NeoGenomics to buy PE-backed clinical oncology lab Genoptix
NeoGenomics has agreed to acquire Carlsbad, California-based Genoptix, a clinical oncology lab, for $125 million in cash and 1 million shares of NeoGenomics common stock. Leerink Partners is providing financial advice to NeoGenomics on the deal with K&L Gates LLP serving as legal counsel. And, William Blair and Company is advised Genoptix while Paul Hastings LLP is serving as legal counsel. Genoptix is backed by Ampersand Capital Partners and 1315 Capital.
29 October 2018•3 mins read
